Metso Files the Form 20-F/A
October 18, 2005 01:50 ET
|
Metso Corporation
HELSINKI, Finland, Oct. 18, 2005 (PRIMEZONE) -- Metso Corporation has yesterday filed with the Securities and Exchange Commission the Form 20-F/A as Amendment No. 1 to its Annual Report on Form 20-F...
Metso files the Form 20-F/A
October 18, 2005 01:46 ET
|
Metso Corporation
Metso Corporation has yesterday filed with the Securities and Exchange Commission the Form 20-F/A as Amendment No. 1 to its Annual Report on Form 20-F filed on March 30, 2005. The Amendment No. 1...
Metso rekisteröi Form 20-F/A -raportin
October 18, 2005 01:45 ET
|
Metso Corporation
Metso-konserni on eilen toimittanut Yhdysvaltojen Securities and Exchange Commissionille Form 20-F/A -raportin, joka korvaa 30.3.2005 päivätyn 20-F -vuosikertomuksen. Raportti kertoo entistä...
Novartis Delivers Strong Growth in First Nine Months of 2005 on Track to Achieve Full-Year Sales and Earnings Objectives
October 18, 2005 01:44 ET
|
Novartis
-- Group nine-month net sales rise 14% in USD (+12% lc), thanks to
strong underlying growth and market share gains in all divisions
-- Pharmaceuticals growth of 11% (+9% lc) for first nine...
Novartis delivers strong growth in first nine months of 2005 on track to achieve full-year sales and earnings objectives
October 18, 2005 01:15 ET
|
Novartis Pharma AG
Group nine-month net sales rise 14% in USD (+12% lc), thanks to strong underlying growth and market share gains in all divisions
Pharmaceuticals growth of 11% (+9% lc) for first nine months...
Novartis erzielt in den ersten neun Monaten des Jahres 2005 ein kräftiges Wachstum und ist damit auf dem besten Weg, die Umsatz- und Gewinnziele für das Gesamtjahr zu erreichen
October 18, 2005 01:15 ET
|
Novartis Pharma AG
Der Nettoumsatz des Konzerns steigt in den ersten neun Monaten um 14% in US-Dollar (+12% in lokalen Währungen) - dank eines kräftigen internen Wachstums und Marktanteilsgewinnen in allen...
Novartis enregistre une croissance soutenue au cours des neuf premiers mois de 2005 et est en bonne voie pour atteindre ses objectifs annuels de chiffre d'affaires et de bénéfices
October 18, 2005 01:14 ET
|
Novartis Pharma AG
Progression de 14% en USD (+12% en monnaies locales) du chiffre d'affaires net du Groupe sur neuf mois grâce à une forte croissance sous-jacente et à des gains de parts de marché dans toutes les...
Novartis delivers strong growth in first nine months of 2005 on track to achieve full-year sales and earnings objectives
October 18, 2005 00:35 ET
|
Novartis Pharma AG
Group nine-month net sales rise 14% in USD (+12% lc), thanks to strong underlying growth and market share gains in all divisions
Pharmaceuticals growth of 11% (+9% lc) for first nine months...
PHA Commission Delivers Bayport and Legislative Consulting Matters
October 17, 2005 19:30 ET
|
Port of Houston Authority
HOUSTON, Oct. 17, 2005 (PRIMEZONE) -- The Port of Houston Authority (PHA) commission approved several recommendations involving contract awards, bids and proposals, professional services and general...
The Pomerantz Firm Announces Additional Details Relevant to the Securities Fraud Litigation Against Refco, Inc. -- RFX
October 17, 2005 18:24 ET
|
Pomerantz LLP
NEW YORK, Oct. 17, 2005 (PRIMEZONE) -- On October 12, 2005, Pomerantz Haudek Block Grossman & Gross LLP (www.pomerantzlaw.com) filed a class action complaint in the United States District Court,...
- July 28, 2024 16:51 ET Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
- July 26, 2024 17:00 ET Premier American Uranium Outlines Multiple Targets for Expansion Drilling at the Cebolleta Project, New Mexico